Skip to main content

Advertisement

Articles

Page 5 of 16

  1. Alzheimer’s disease is characterized by aggregated β-amyloid and tau proteins, but the clinical presentations and patterns of brain atrophy vary substantially. A part of this heterogeneity may be linked to the...

    Authors: Niklas Mattsson, Rik Ossenkoppele, Ruben Smith, Olof Strandberg, Tomas Ohlsson, Jonas Jögi, Sebastian Palmqvist, Erik Stomrud and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2018 10:77

    Content type: Research

    Published on:

  2. Amyloid pathology is the pathological hallmark in Alzheimer’s disease (AD) and can precede clinical dementia by decades. So far it remains unclear how amyloid pathology leads to cognitive impairment and dement...

    Authors: Elles Konijnenberg, Stephen F. Carter, Mara ten Kate, Anouk den Braber, Jori Tomassen, Chinenye Amadi, Linda Wesselman, Hoang-Ton Nguyen, Jacoba A. van de Kreeke, Maqsood Yaqub, Matteo Demuru, Sandra D. Mulder, Arjan Hillebrand, Femke H. Bouwman, Charlotte E. Teunissen, Erik H. Serné…

    Citation: Alzheimer's Research & Therapy 2018 10:75

    Content type: Research

    Published on:

  3. Imaging agents capable of quantifying the brain’s tau aggregates will allow a more precise staging of Alzheimer’s disease (AD). The aim of the present study was to examine the in vitro properties as well as th...

    Authors: Tharick A. Pascoal, Monica Shin, Min Su Kang, Mira Chamoun, Daniel Chartrand, Sulantha Mathotaarachchi, Idriss Bennacef, Joseph Therriault, Kok Pin Ng, Robert Hopewell, Reda Bouhachi, Hung-Hsin Hsiao, Andrea L. Benedet, Jean-Paul Soucy, Gassan Massarweh, Serge Gauthier…

    Citation: Alzheimer's Research & Therapy 2018 10:74

    Content type: Research

    Published on:

  4. Since the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared pot...

    Authors: Craig W. Ritchie, Tom C. Russ, Sube Banerjee, Bob Barber, Andrew Boaden, Nick C. Fox, Clive Holmes, Jeremy D. Isaacs, Ira Leroi, Simon Lovestone, Matt Norton, John O’Brien, Jim Pearson, Richard Perry, James Pickett, Adam D. Waldman…

    Citation: Alzheimer's Research & Therapy 2018 10:73

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2017 9:85

  5. Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. H...

    Authors: Arno de Wilde, Marieke M. van Buchem, René H. J. Otten, Femke Bouwman, Andrew Stephens, Frederik Barkhof, Philip Scheltens and Wiesje M. van der Flier

    Citation: Alzheimer's Research & Therapy 2018 10:72

    Content type: Review

    Published on:

  6. A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer’s disease (AD).

    Authors: Piotr Lewczuk, Natalia Ermann, Ulf Andreasson, Christian Schultheis, Jana Podhorna, Philipp Spitzer, Juan Manuel Maler, Johannes Kornhuber, Kaj Blennow and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2018 10:71

    Content type: Research

    Published on:

  7. Processing of degraded speech is a promising model for understanding communication under challenging listening conditions, core auditory deficits and residual capacity for perceptual learning and cerebral plas...

    Authors: Chris J. D. Hardy, Charles R. Marshall, Rebecca L. Bond, Lucy L. Russell, Katrina Dick, Cono Ariti, David L. Thomas, Sonya J. Ross, Jennifer L. Agustus, Sebastian J. Crutch, Jonathan D. Rohrer, Doris-Eva Bamiou and Jason D. Warren

    Citation: Alzheimer's Research & Therapy 2018 10:70

    Content type: Research

    Published on:

  8. Mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) cause autosomal dominant forms of Alzheimer disease (ADAD). More than 280 pathogenic mutations have been reported in APP

    Authors: Celeste M. Karch, Damián Hernández, Jen-Chyong Wang, Jacob Marsh, Alex W. Hewitt, Simon Hsu, Joanne Norton, Denise Levitch, Tamara Donahue, Wendy Sigurdson, Bernardino Ghetti, Martin Farlow, Jasmeer Chhatwal, Sarah Berman, Carlos Cruchaga, John C. Morris…

    Citation: Alzheimer's Research & Therapy 2018 10:69

    Content type: Research

    Published on:

  9. A subset of patients with the nonfluent variant of primary progressive aphasia (PPA) exhibit concomitant single-word comprehension problems, constituting a ‘mixed variant’ phenotype. This phenotype is rare and...

    Authors: Jolien Schaeverbeke, Silvy Gabel, Karen Meersmans, Rose Bruffaerts, Antonietta Gabriella Liuzzi, Charlotte Evenepoel, Eva Dries, Karen Van Bouwel, Anne Sieben, Yolande Pijnenburg, Ronald Peeters, Guy Bormans, Koen Van Laere, Michel Koole, Patrick Dupont and Rik Vandenberghe

    Citation: Alzheimer's Research & Therapy 2018 10:68

    Content type: Research

    Published on:

  10. Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (P...

    Authors: Simon Hsu, Brian A. Gordon, Russ Hornbeck, Joanne B. Norton, Denise Levitch, Adia Louden, Ellen Ziegemeier, Robert Laforce Jr., Jasmeer Chhatwal, Gregory S. Day, Eric McDade, John C. Morris, Anne M. Fagan, Tammie L. S. Benzinger, Alison M. Goate, Carlos Cruchaga…

    Citation: Alzheimer's Research & Therapy 2018 10:67

    Content type: Research

    Published on:

  11. Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with AD pathology, amyloid pathology, and ta...

    Authors: Loïc Dayon, Antonio Núñez Galindo, Jérôme Wojcik, Ornella Cominetti, John Corthésy, Aikaterini Oikonomidi, Hugues Henry, Martin Kussmann, Eugenia Migliavacca, India Severin, Gene L. Bowman and Julius Popp

    Citation: Alzheimer's Research & Therapy 2018 10:66

    Content type: Research

    Published on:

  12. A need exists for easily administered assessment tools to detect mild cognitive changes that are more comprehensive than screening tests but shorter than a neuropsychological battery and that can be administer...

    Authors: Morris Freedman, Larry Leach, M. Carmela Tartaglia, Kathryn A. Stokes, Yael Goldberg, Robyn Spring, Nima Nourhaghighi, Tom Gee, Stephen C. Strother, Mohammad O. Alhaj, Michael Borrie, Sultan Darvesh, Alita Fernandez, Corinne E. Fischer, Jennifer Fogarty, Barry D. Greenberg…

    Citation: Alzheimer's Research & Therapy 2018 10:65

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:120

  13. There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Informatio...

    Authors: Isabelle Bos, Stephanie Vos, Rik Vandenberghe, Philip Scheltens, Sebastiaan Engelborghs, Giovanni Frisoni, José Luis Molinuevo, Anders Wallin, Alberto Lleó, Julius Popp, Pablo Martinez-Lage, Alison Baird, Richard Dobson, Cristina Legido-Quigley, Kristel Sleegers, Christine Van Broeckhoven…

    Citation: Alzheimer's Research & Therapy 2018 10:64

    Content type: Research

    Published on:

  14. Plasma amyloid-β (Aβ) levels are increasingly studied as a potential accessible marker of cognitive impairment and dementia. However, it remains underexplored whether plasma Aβ levels including the novel Aβ pe...

    Authors: Saima Hilal, Frank J. Wolters, Marcel M. Verbeek, Hugo Vanderstichele, M. Kamran Ikram, Erik Stoops, M. Arfan Ikram and Meike W. Vernooij

    Citation: Alzheimer's Research & Therapy 2018 10:63

    Content type: Research

    Published on:

  15. Selecting high-risk participants for dementia prevention trials based on a modifiable dementia risk score may be advantageous, as it increases the opportunity for intervention. We studied whether a multi-domai...

    Authors: Tessa van Middelaar, Marieke P. Hoevenaar-Blom, Willem A. van Gool, Eric P. Moll van Charante, Jan-Willem van Dalen, Kay Deckers, Sebastian Köhler and Edo Richard

    Citation: Alzheimer's Research & Therapy 2018 10:62

    Content type: Research

    Published on:

  17. The performance of [18F]flutemetamol amyloid PET against histopathological standards of truth was the subject of our recent article in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (2017;9:25...

    Authors: Milos D. Ikonomovic, Enrico R. Fantoni, Gill Farrar and Stephen Salloway

    Citation: Alzheimer's Research & Therapy 2018 10:60

    Content type: Viewpoint

    Published on:

  18. Alzheimer’s disease (AD) is a multifactorial and complex neuropathology that involves impairment of many intricate molecular mechanisms. Despite recent advances, AD pathophysiological characterization remains ...

    Authors: D. M. Vargas, M. A. De Bastiani, E. R. Zimmer and F. Klamt

    Citation: Alzheimer's Research & Therapy 2018 10:59

    Content type: Research

    Published on:

  19. Increasing evidence suggests that cerebral vascular dysfunction is associated with the early stages of Alzheimer’s disease (AD). Vascular endothelial growth factor (VEGF) is one of the key players involved in ...

    Authors: Ananya Chakraborty, Madhurima Chatterjee, Harry Twaalfhoven, Marta Del Campo Milan, Charlotte E. Teunissen, Philip Scheltens, Ruud D. Fontijn, Wiesje M. van Der Flier and Helga E. de Vries

    Citation: Alzheimer's Research & Therapy 2018 10:58

    Content type: Research

    Published on:

  20. Psycho-affective states or traits such as stress, depression, anxiety and neuroticism are known to affect sleep, cognition and mental health and well-being in aging populations and to be associated with increa...

    Authors: Gaël Chételat, Antoine Lutz, Eider Arenaza-Urquijo, Fabienne Collette, Olga Klimecki and Natalie Marchant

    Citation: Alzheimer's Research & Therapy 2018 10:57

    Content type: Viewpoint

    Published on:

  21. Upon publication of this article [1], it was noticed that there were some inconsistencies in Tables 1, 2 and 3. Some of the superscript letters were incorrectly assigned. Please see below the correct tables:

    Authors: Isabelle Bos, Frans R. Verhey, Inez H. G. B. Ramakers, Heidi I. L. Jacobs, Hilkka Soininen, Yvonne Freund-Levi, Harald Hampel, Magda Tsolaki, Åsa K. Wallin, Mark A. van Buchem, Ania Oleksik, Marcel M. Verbeek, Marcel Olde Rikkert, Wiesje M. van der Flier, Philip Scheltens, Pauline Aalten…

    Citation: Alzheimer's Research & Therapy 2018 10:56

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2017 9:101

  22. Truncated mis-disordered tau protein plays an important role in the pathogenesis of Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Tau294–305, an epitope in the truncated tau, is essential for pathol...

    Authors: Mei Ji, Xi-xiu Xie, Dong-qun Liu, Xiao-lin Yu, Yue Zhang, Ling-Xiao Zhang, Shao-wei Wang, Ya-ru Huang and Rui-tian Liu

    Citation: Alzheimer's Research & Therapy 2018 10:55

    Content type: Research

    Published on:

  23. Alzheimer’s disease (AD) is characterized by physiologically endogenous proteins amyloid beta (Aβ) and tau undergoing a conformational change and accumulating as soluble oligomers and insoluble aggregates. Tau...

    Authors: Krystal Herline, Frances Prelli, Pankaj Mehta, Claire MacMurray, Fernando Goñi and Thomas Wisniewski

    Citation: Alzheimer's Research & Therapy 2018 10:54

    Content type: Research

    Published on:

  25. Synaptic and axonal loss are two major mechanisms underlying Alzheimer’s disease (AD) pathogenesis, and biomarkers reflecting changes in these cellular processes are needed for early diagnosis and monitoring t...

    Authors: Madhurima Chatterjee, Marta Del Campo, Tjado H. J. Morrema, Matthijs de Waal, Wiesje M. van der Flier, Jeroen J. M. Hoozemans and Charlotte E. Teunissen

    Citation: Alzheimer's Research & Therapy 2018 10:52

    Content type: Research

    Published on:

  26. Drugs for dementia have been available in England since 1997. Since their launch, there have been several changes to national guidelines and initiatives that may have influenced prescribing. These include chan...

    Authors: Venexia M. Walker, Neil M. Davies, Patrick G. Kehoe and Richard M. Martin

    Citation: Alzheimer's Research & Therapy 2018 10:51

    Content type: Research

    Published on:

  27. We investigated the effects of lifetime cumulative ginseng intake on cognitive function in a community-dwelling population-based prospective cohort of Korean elders.

    Authors: Silvia Kyungjin Lho, Tae Hui Kim, Kyung Phil Kwak, Kayoung Kim, Bong Jo Kim, Shin Gyeom Kim, Jeong Lan Kim, Tae Hyun Kim, Seok Woo Moon, Jae Young Park, Joon Hyuk Park, Seonjeong Byun, Seung Wan Suh, Ji Young Seo, Yoonseop So, Seung-Ho Ryu…

    Citation: Alzheimer's Research & Therapy 2018 10:50

    Content type: Research

    Published on:

  28. Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer’s disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance rema...

    Authors: Stina Syvänen, Greta Hultqvist, Tobias Gustavsson, Astrid Gumucio, Hanna Laudon, Linda Söderberg, Martin Ingelsson, Lars Lannfelt and Dag Sehlin

    Citation: Alzheimer's Research & Therapy 2018 10:49

    Content type: Research

    Published on:

  29. The ε4 allele of the apolipoprotein E gene (APOE-ε4) is the strongest genetic factor for late-onset Alzheimer’s disease. During middle age, cognitively healthy APOE-ε4 carriers already show several brain alterati...

    Authors: Grégory Operto, Raffaele Cacciaglia, Oriol Grau-Rivera, Carles Falcon, Anna Brugulat-Serrat, Pablo Ródenas, Rubén Ramos, Sebastián Morán, Manel Esteller, Nuria Bargalló, José Luis Molinuevo and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2018 10:48

    Content type: Research

    Published on:

  30. The contribution of psychological factors to brain health and resilience remains poorly investigated. Furthermore, their possible interaction with ‘classical’ cognitive reserve (CR) estimates in predicting per...

    Authors: David Bartrés-Faz, Gabriele Cattaneo, Javier Solana, Josep M. Tormos and Alvaro Pascual-Leone

    Citation: Alzheimer's Research & Therapy 2018 10:47

    Content type: Research

    Published on:

  31. In patients with frontotemporal dementia, it has been shown that brain atrophy occurs earliest in the anterior cingulate, insula and frontal lobes. We used visual rating scales to investigate whether identifyi...

    Authors: Giorgio G. Fumagalli, Paola Basilico, Andrea Arighi, Martina Bocchetta, Katrina M. Dick, David M. Cash, Sophie Harding, Matteo Mercurio, Chiara Fenoglio, Anna M. Pietroboni, Laura Ghezzi, John van Swieten, Barbara Borroni, Alexandre de Mendonça, Mario Masellis, Maria C. Tartaglia…

    Citation: Alzheimer's Research & Therapy 2018 10:46

    Content type: Research

    Published on:

  32. The range of onset ages within some PSEN1 families is wide, and a few cases of reduced penetrance of PSEN1 mutations have been reported. However, published data on reduced penetrance have been limited to clinical...

    Authors: Steinunn Thordardottir, Elena Rodriguez-Vieitez, Ove Almkvist, Daniel Ferreira, Laure Saint-Aubert, Anne Kinhult-Ståhlbom, Håkan Thonberg, Michael Schöll, Eric Westman, Anders Wall, Maria Eriksdotter, Henrik Zetterberg, Kaj Blennow, Agneta Nordberg and Caroline Graff

    Citation: Alzheimer's Research & Therapy 2018 10:45

    Content type: Research

    Published on:

  33. The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer’s disease.

    Authors: Basil H. Ridha, Sebastian Crutch, Dawn Cutler, Christopher Frost, William Knight, Suzie Barker, Norah Epie, Elizabeth K. Warrington, Riitta Kukkastenvehmas, Jane Douglas and Martin N. Rossor

    Citation: Alzheimer's Research & Therapy 2018 10:44

    Content type: Research

    Published on:

  34. Vitamin D deficiency is associated with an increased risk of Alzheimer’s disease and increased beta-amyloid (Aβ) in animals. Hence we sought to investigate the relationship between plasma 25-hydroxyvitamin D (...

    Authors: Fati Nourhashemi, Claudie Hooper, Christelle Cantet, Catherine Féart, Isabelle Gennero, Pierre Payoux, Anne Sophie Salabert, Sophie Guyonnet, Philipe De Souto Barreto and Bruno Vellas

    Citation: Alzheimer's Research & Therapy 2018 10:43

    Content type: Research

    Published on:

  35. Mild cognitive impairment (MCI) is a heterogeneous syndrome resulting from Alzheimer’s disease (AD) as well as to non-AD and non-neurodegenerative conditions. A subset of patients with amnestic MCI (aMCI) pres...

    Authors: Chiara Cerami, Alessandra Dodich, Sandro Iannaccone, Giuseppe Magnani, Roberto Santangelo, Luca Presotto, Alessandra Marcone, Luigi Gianolli, Stefano F. Cappa and Daniela Perani

    Citation: Alzheimer's Research & Therapy 2018 10:42

    Content type: Research

    Published on:

  36. With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential thera...

    Authors: Elisa Semler, Sarah Anderl-Straub, Ingo Uttner, Janine Diehl-Schmid, Adrian Danek, Beate Einsiedler, Klaus Fassbender, Klaus Fliessbach, Hans-Jürgen Huppertz, Holger Jahn, Johannes Kornhuber, Bernhard Landwehrmeyer, Martin Lauer, Rainer Muche, Johannes Prudlo, Anja Schneider…

    Citation: Alzheimer's Research & Therapy 2018 10:41

    Content type: Research

    Published on:

  37. Alzheimer’s disease (AD) is a devastating neurodegenerative disorder bearing multiple pathological hallmarks suggestive of complex cellular/molecular interplay during pathogenesis. Transgenic mice and nonhuman...

    Authors: Feng-Qin Zhou, Juan Jiang, Chelsea M. Griffith, Peter R. Patrylo, Huaibin Cai, Yaping Chu and Xiao-Xin Yan

    Citation: Alzheimer's Research & Therapy 2018 10:40

    Content type: Research

    Published on:

  38. Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood bi...

    Authors: Andre Strydom, Amanda Heslegrave, Carla M. Startin, Kin Y. Mok, John Hardy, Jurgen Groet, Dean Nizetic and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2018 10:39

    Content type: Research

    Published on:

  39. Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor ...

    Authors: Terence Fullerton, Brendon Binneman, William David, Marielle Delnomdedieu, James Kupiec, Peter Lockwood, Jessica Mancuso, Jeffrey Miceli and Joanne Bell

    Citation: Alzheimer's Research & Therapy 2018 10:38

    Content type: Research

    Published on:

  41. Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compar...

    Authors: Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin and David Henley

    Citation: Alzheimer's Research & Therapy 2018 10:36

    Content type: Research

    Published on:

  42. We explored the presence of both reserve and resilience in late-converter mild cognitive impairment due to Alzheimer’s disease (MCI-AD) and in patients with slowly progressing amyloid-positive MCI by assessing...

    Authors: Matteo Bauckneht, Andrea Chincarini, Roberta Piva, Dario Arnaldi, Nicola Girtler, Federico Massa, Matteo Pardini, Matteo Grazzini, Hulya Efeturk, Marco Pagani, Gianmario Sambuceti, Flavio Nobili and Silvia Morbelli

    Citation: Alzheimer's Research & Therapy 2018 10:35

    Content type: Research

    Published on:

  44. Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of underlying Alzheimer’s disease (AD) pathology in mild cognitive impairment (MCI). However, CSF biomarker-based classification oft...

    Authors: Inês Baldeiras, Isabel Santana, Maria João Leitão, Helena Gens, Rui Pascoal, Miguel Tábuas-Pereira, José Beato-Coelho, Diana Duro, Maria Rosário Almeida and Catarina Resende Oliveira

    Citation: Alzheimer's Research & Therapy 2018 10:33

    Content type: Research

    Published on:

  45. Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer’s disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such ...

    Authors: Ross W. Paterson, Catherine F. Slattery, Teresa Poole, Jennifer M. Nicholas, Nadia K. Magdalinou, Jamie Toombs, Miles D. Chapman, Michael P. Lunn, Amanda J. Heslegrave, Martha S Foiani, Philip S. J. Weston, Ashvini Keshavan, Jonathan D. Rohrer, Martin N. Rossor, Jason D. Warren, Catherine J. Mummery…

    Citation: Alzheimer's Research & Therapy 2018 10:32

    Content type: Research

    Published on:

  46. We explored the diagnostic performance of cerebrospinal fluid (CSF) biomarkers in allowing differentiation between frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD), as well as between FTLD...

    Authors: Joery Goossens, Maria Bjerke, Sara Van Mossevelde, Tobi Van den Bossche, Johan Goeman, Bart De Vil, Anne Sieben, Jean-Jacques Martin, Patrick Cras, Peter Paul De Deyn, Christine Van Broeckhoven, Julie van der Zee and Sebastiaan Engelborghs

    Citation: Alzheimer's Research & Therapy 2018 10:31

    Content type: Research

    Published on:

  47. Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several...

    Authors: Charlotte E. Teunissen, Markus Otto, Sebastiaan Engelborghs, Sanna-Kaisa Herukka, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleó, Armand Perret-Liaudet, Hayrettin Tumani, Martin R. Turner, Marcel M. Verbeek, Jens Wiltfang, Henrik Zetterberg, Lucilla Parnetti and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2018 10:30

    Content type: Review

    Published on:

  48. Substantial evidence indicates that the relationship between blood pressure (BP) measures and cognitive functioning is inconsistent, complex, and age-related. Pulse pressure (PP), which can not only reflect ar...

    Authors: Tingting Sha, Wenwei Cheng and Yan Yan

    Citation: Alzheimer's Research & Therapy 2018 10:29

    Content type: Research

    Published on:

  49. Recent evidence derived from functional magnetic resonance imaging (fMRI) studies suggests that functional hubs (i.e., highly connected brain regions) are important for mental health. We found recently that gl...

    Authors: Nicolai Franzmeier, Julia Hartmann, Alexander N. W. Taylor, Miguel Á. Araque-Caballero, Lee Simon-Vermot, Lana Kambeitz-Ilankovic, Katharina Bürger, Cihan Catak, Daniel Janowitz, Claudia Müller, Birgit Ertl-Wagner, Robert Stahl, Martin Dichgans, Marco Duering and Michael Ewers

    Citation: Alzheimer's Research & Therapy 2018 10:28

    Content type: Research

    Published on:

  50. Dementia due to Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most common neurodegenerative causes of dementia. They commonly occur together, especially in older people, but clinical...

    Authors: Alan J. Thomas, Fariba Mahin-Babaei, Mohammad Saidi, Debbie Lett, John Paul Taylor, Lauren Walker and Johannes Attems

    Citation: Alzheimer's Research & Therapy 2018 10:27

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Advertisement

Alzheimer's Research & Therapy

ISSN: 1758-9193